Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme Bristol Myers Squibb today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo to the current standard of care versus placebo plus the standard of care in patients with newly diagnosed glioblastoma multiforme with O6-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the t...
United States South Korea Bristol Myers Squibb Company Opdivo Drug Administration Oncology Development Program
Source: investingnews.com